Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee

Pediatric Infectious Disease Journal

Volumn 32, Issue 6, 2013, Pages 604-609

  Halasa, Natasha B ^a   Grijalva, Carlos G ^b   Arbogast, Patrick G ^b   Talbot, Thomas R ^b   Craig, Allen S ^b,c   Griffin, Marie R ^b,d   Schaffner, William ^b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TENNESSEE DEPARTMENT OF HEALTH   (United States)

^d Veterans Affairs   (United States)

Author keywords

Antibiotics; Bacteremia; Resistance; Streptococcus pneumoniae

Indexed keywords

PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; DISEASE SURVEILLANCE; FEMALE; HUMAN; LABORATORY; MAJOR CLINICAL STUDY; MALE; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TENNESSEE; YOUNG ADULT;

EID: 84879246729     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318287fe0d     Document Type: Article

References (40)

1. Ghaffar F. The safety of 7-valent pneumococcal conjugate vaccine. Expert Opin Drug Saf. 2005;4:631-636.
2. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366.
3. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1-35.
4. Hausdorff WP, Bryant J, Kloek C, et al. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis. 2000;30:122-140.
5. Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100-121.
6. Butler JC, Breiman RF, Lipman HB, et al. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis. 1995;171:885-889.
7. Black S, Shinefield H, Baxter R, et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine. 2006;24(suppl 2):S2-S80.
8. Flannery B, Schrag S, Bennett NM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004;291:2197-2203.
9. Whitney CG, Farley MM, Hadler J, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
10. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295:1668-1674.
11. Talbot TR, Poehling KA, Hartert TV, et al. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. Pediatr Infect Dis J. 2004;23:726-731.
12. Shah SS, Ratner AJ. Trends in invasive pneumococcal disease-associated hospitalizations. Clin Infect Dis. 2006;42:e1-e5.
13. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
14. Pilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
15. Rosen JB, Thomas AR, Lexau CA, et al.; CDC Emerging Infections Program Network. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis. 2011;53:137-143.
16. Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine. 2008;26:4947-4954.
17. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
18. Talbot TR, Poehling KA, Hartert TY et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2004;39:641-648.
19. Kyaw MH, Lynfield R, Schaffner W, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455-1463.
20. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-1792.
21. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298:1772-1778.
22. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26:468-472.
23. Jacobs MR, Good CE, Beall B, et al. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae in Cleveland: a quarter-century experience. J Clin Microbiol. 2008;46:982-990.
24. Pai R, Moore MR, Pilishvili T, et al.; Active Bacterial Core Surveillance Team. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988-1995.
25. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016-1027.
26. Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J. 2012;31:249-254.
27. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1-24.
28. Recommended adult immunization schedule - United States, 2002-2003. MMWR Morb Mortal Wkly Rep. 2002;51:904-908.
29. Schuchat A, Hilger T, Zell E, et al.; Active Bacterial Core Surveillance Team of the Emerging Infections Program Network. Active bacterial core surveillance of the emerging infections program network. Emerging Infect Dis. 2001;7:92-99.
30. Schuchat A, Broome CV, Hightower A, et al. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. JAMA. 1991;265:3275-3279.
31. Patil A, Huard D, Fonnesbeck CJ. PyMC: Bayesian Stochastic Modelling in Python. J Stat Softw. 2010;35:1-81.
32. Munoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174-182.
33. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346-1354.
34. Gonzalez BE, Hulten KG, Lamberth L, et al.; U.S. Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr Infect Dis J. 2006;25:301-305.
35. Whitney CG, Farley MM, Hadler J, et al.; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917-1924.
36. Schrag SJ, McGee L, Whitney CG, et al.; Active Bacterial Core Surveillance Team. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother. 2004;48:3016-3023.
37. Steenhoff AP, Shah SS, Ratner AJ, et al. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis. 2006;42:907-914.
38. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J. 2007;26:123-128.
39. Tsigrelis C, Tleyjeh IM, Huskins WC, et al. Incidence of invasive pneumococcal disease among children after introduction of a 7-valent pneumococcal conjugate vaccine: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2009;84:871-875.
40. Moore MR, Whitney CG. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? Clin Infect Dis. 2008;46:183-185.